Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CD20-targeted CAR-T immunotherapy
DRUG CLASS:
CD20-targeted CAR-T immunotherapy
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
IMPT-314 (2)
ADI-001 (1)
MB-106 (1)
JNJ-4496 (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
CAR-20/19-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART20 (0)
CBM-C20.1 (0)
CD19/CD20 CAR T-cells (0)
CD20-CART (0)
CD20-CD19 cCAR T cells (0)
ELC-301 (0)
JNJ-9530 (0)
KITE-363 (0)
LCAR-AIO (0)
LY007 (0)
MB-CART20.1 (0)
PBCAR 20A (0)
RG6540 (0)
U16 (0)
UCART20x22 (0)
YTS101 (0)
autologous TriCAR T (0)
bbT369 (0)
multi-CAR-T cell therapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
MB-CART2019.1 (0)
IMPT-314 (2)
ADI-001 (1)
MB-106 (1)
JNJ-4496 (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
CAR-20/19-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART20 (0)
CBM-C20.1 (0)
CD19/CD20 CAR T-cells (0)
CD20-CART (0)
CD20-CD19 cCAR T cells (0)
ELC-301 (0)
JNJ-9530 (0)
KITE-363 (0)
LCAR-AIO (0)
LY007 (0)
MB-CART20.1 (0)
PBCAR 20A (0)
RG6540 (0)
U16 (0)
UCART20x22 (0)
YTS101 (0)
autologous TriCAR T (0)
bbT369 (0)
multi-CAR-T cell therapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
MB-CART2019.1 (0)
›
Associations
(6)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PRO00037171) (NCT04186520)
Phase 1/2
Medical College of Wisconsin
Medical College of Wisconsin
Recruiting
Phase 1/2
Medical College of Wisconsin
Recruiting
Last update posted :
02/18/2025
Initiation :
05/18/2020
Primary completion :
06/30/2026
Completion :
06/01/2028
BCL2
|
CAR-20/19-T Cells
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05421663)
Phase 1
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Recruiting
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
02/06/2025
Initiation :
08/12/2022
Primary completion :
05/29/2026
Completion :
12/29/2028
CD20
|
CD20 positive
|
prizloncabtagene autoleucel (JNJ-4496)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (CRC-403) (NCT05169489)
Phase 1/2
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Active, not recruiting
Phase 1/2
Regeneron Pharmaceuticals
Active, not recruiting
Last update posted :
02/03/2025
Initiation :
01/24/2022
Primary completion :
08/31/2025
Completion :
08/31/2025
BCL2 • BCL6
|
BCL6 rearrangement • BCL2 rearrangement
|
bbT369
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088)
Phase 1
Sumithira Vasu
Sumithira Vasu
Recruiting
Phase 1
Sumithira Vasu
Recruiting
Last update posted :
02/03/2025
Initiation :
06/30/2022
Primary completion :
04/30/2025
Completion :
07/31/2026
CD20 • CD19 • CD22
|
CD20 positive
|
cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
Study of IMPT-314 in R/R Aggressive B-cell NHL (MPCT-012L) (NCT05826535)
Phase 1/2
ImmPACT Bio
ImmPACT Bio
Recruiting
Phase 1/2
ImmPACT Bio
Recruiting
Last update posted :
01/14/2025
Initiation :
05/09/2023
Primary completion :
06/01/2025
Completion :
12/01/2029
BCL2 • BCL6
|
BCL6 rearrangement • BCL2 rearrangement
|
rondecabtagene autoleucel (IMPT-314)
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma (NCT06532643)
Phase 1
Shanghai First Song Biotechnology Co., LTD
Shanghai First Song Biotechnology Co., LTD
Recruiting
Phase 1
Shanghai First Song Biotechnology Co., LTD
Recruiting
Last update posted :
09/19/2024
Initiation :
08/24/2023
Primary completion :
09/01/2025
Completion :
09/01/2026
TNFRSF8
|
cyclophosphamide • fludarabine IV
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)
Phase 1/2
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Active, not recruiting
Phase 1/2
Fred Hutchinson Cancer Center
Active, not recruiting
Last update posted :
06/12/2024
Initiation :
12/05/2017
Primary completion :
03/29/2024
Completion :
11/16/2037
BCL2
|
CD20 expression
|
cyclophosphamide • fludarabine IV • MB-106
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (NCT06014762)
Phase 1
Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc.
Recruiting
Phase 1
Poseida Therapeutics, Inc.
Recruiting
Last update posted :
06/03/2024
Initiation :
04/16/2024
Primary completion :
03/01/2029
Completion :
03/01/2041
CD20 • CD5 • FCER2
|
CD20 positive
|
RG6540 • rimiducid (AP1903)
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04036019)
Phase 1
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai Tongji Hospital, Tongji Univer...
Completed
Phase 1
Shanghai Tongji Hospital, Tongji University Sch...
Completed
Last update posted :
05/28/2024
Initiation :
08/20/2019
Primary completion :
06/20/2022
Completion :
06/20/2022
CD20
|
JNJ-9530
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (NCT05292898)
Phase 1
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Disease...
Active, not recruiting
Phase 1
Institute of Hematology & Blood Diseases Hospit...
Active, not recruiting
Last update posted :
05/14/2024
Initiation :
03/14/2022
Primary completion :
07/01/2024
Completion :
07/01/2026
CD20 • CD22
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) (NCT06002659)
Phase 1/2
Uppsala University
Uppsala University
Recruiting
Phase 1/2
Uppsala University
Recruiting
Last update posted :
05/09/2024
Initiation :
05/01/2024
Primary completion :
12/30/2027
Completion :
12/30/2027
CD20
|
cyclophosphamide • fludarabine IV • ELC-301
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (NCT03870945)
Phase 1/2
Miltenyi Biomedicine GmbH
Miltenyi Biomedicine GmbH
Active, not recruiting
Phase 1/2
Miltenyi Biomedicine GmbH
Active, not recruiting
Last update posted :
04/30/2024
Initiation :
02/25/2019
Primary completion :
12/17/2020
Completion :
12/31/2025
BCL2 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
zamtocabtagene autoleucel (MB-CART2019.1)
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) (NCT04844866)
Phase 2
Miltenyi Biomedicine GmbH
Miltenyi Biomedicine GmbH
Recruiting
Phase 2
Miltenyi Biomedicine GmbH
Recruiting
Last update posted :
04/30/2024
Initiation :
08/18/2021
Primary completion :
12/31/2024
Completion :
07/31/2027
BCL2 • CD19 • BCL6
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
MB-CART20.1 Lymphoma (NCT03664635)
Phase 1/2
Miltenyi Biomedicine GmbH
Miltenyi Biomedicine GmbH
Active, not recruiting
Phase 1/2
Miltenyi Biomedicine GmbH
Active, not recruiting
Last update posted :
04/23/2024
Initiation :
09/25/2018
Primary completion :
09/30/2024
Completion :
09/30/2024
CD20
|
MB-CART20.1
An Evaluation of LY007 Cell Injection for r/r B-NHL (NCT06364852)
Phase 1
Ruijin Hospital
Ruijin Hospital
Recruiting
Phase 1
Ruijin Hospital
Recruiting
Last update posted :
04/15/2024
Initiation :
12/25/2021
Primary completion :
08/31/2024
Completion :
05/31/2026
CD20
|
CD20 expression
|
LY007
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) (NCT05607420)
Phase 1/2
Cellectis S.A.
Cellectis S.A.
Recruiting
Phase 1/2
Cellectis S.A.
Recruiting
Last update posted :
03/01/2024
Initiation :
11/01/2022
Primary completion :
11/01/2027
Completion :
11/01/2027
BCL2 • BCL6 • CD22
|
CD20 positive • BCL6 rearrangement • BCL2 rearrangement
|
Campath (alemtuzumab) • UCART20x22
An Evaluation of LY007 Cell Injection for r/r B-NHL (NCT06279611)
Phase 1
Shanghai Longyao Biotechnology Inc., Ltd.
Shanghai Longyao Biotechnology Inc., Ltd.
Recruiting
Phase 1
Shanghai Longyao Biotechnology Inc., Ltd.
Recruiting
Last update posted :
02/28/2024
Initiation :
12/25/2021
Primary completion :
08/31/2024
Completion :
05/31/2026
CD20
|
CD20 expression
|
LY007
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (NCT04697940)
Phase 1/2
Han weidong
Han weidong
Recruiting
Phase 1/2
Han weidong
Recruiting
Last update posted :
02/07/2024
Initiation :
12/15/2020
Primary completion :
12/30/2024
Completion :
12/30/2025
BCL2 • CCND1 • BCL6
|
Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • decitabine • fludarabine IV
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (MB106-CD20-001) (NCT05360238)
Phase 1/2
Mustang Bio
Mustang Bio
Recruiting
Phase 1/2
Mustang Bio
Recruiting
Last update posted :
12/20/2023
Initiation :
05/24/2022
Primary completion :
09/01/2026
Completion :
09/01/2026
BCL2 • CD20 • BCL6
|
CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
|
MB-106
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04007029)
Phase 1
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Recruiting
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
10/06/2023
Initiation :
10/04/2019
Primary completion :
08/01/2024
Completion :
08/01/2025
CD20 • CD8 • CD4
|
CD19 expression
|
cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • cyclophosphamide intravenous
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05768529)
Phase 1/2
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Shanghai Unicar-Therapy Bio-medicine Te...
Recruiting
Phase 1/2
Shanghai Unicar-Therapy Bio-medicine Technology...
Recruiting
Last update posted :
09/21/2023
Initiation :
03/28/2023
Primary completion :
12/31/2024
Completion :
12/31/2026
IL6
|
CD20 positive • CD20 negative
|
cyclophosphamide • U16
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206)
Phase 1
Medical College of Wisconsin
Medical College of Wisconsin
Active, not recruiting
Phase 1
Medical College of Wisconsin
Active, not recruiting
Last update posted :
08/23/2023
Initiation :
06/30/2022
Primary completion :
02/01/2025
Completion :
02/01/2026
BCL2
|
CAR20.19.22 T
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (NCT05318963)
Phase 1
Qiu Lugui
Qiu Lugui
Recruiting
Phase 1
Qiu Lugui
Recruiting
Last update posted :
08/03/2023
Initiation :
03/14/2022
Primary completion :
06/30/2024
Completion :
06/30/2026
CD20 • CD22
|
CD19 expression
|
cyclophosphamide • LCAR-AIO
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04316624)
Phase 1
Institute of Hematology & Blood Diseases Hospital
Institute of Hematology & Blood Disease...
Completed
Phase 1
Institute of Hematology & Blood Diseases Hospital
Completed
Last update posted :
07/19/2023
Initiation :
09/29/2019
Primary completion :
02/08/2023
Completion :
02/08/2023
CD20
|
CD20 positive
|
JNJ-9530
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (ELEVATION) (NCT05800977)
Phase 1b/2
Cellular Biomedicine Group Ltd.
Cellular Biomedicine Group Ltd.
Recruiting
Phase 1b/2
Cellular Biomedicine Group Ltd.
Recruiting
Last update posted :
04/06/2023
Initiation :
02/22/2023
Primary completion :
03/31/2027
Completion :
03/31/2027
BCL2 • CD20 • CD19 • BCL6
|
CD20 positive • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
prizloncabtagene autoleucel (JNJ-4496)
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195)
Phase 1/2
Precision BioSciences, Inc.
Precision BioSciences, Inc.
Completed
Phase 1/2
Precision BioSciences, Inc.
Completed
Last update posted :
01/31/2023
Initiation :
03/24/2020
Primary completion :
06/24/2021
Completion :
06/24/2021
CD20
|
cyclophosphamide • fludarabine IV • PBCAR 20A
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (NCT04260945)
Phase 1
Hebei Yanda Ludaopei Hospital
Hebei Yanda Ludaopei Hospital
Completed
Phase 1
Hebei Yanda Ludaopei Hospital
Completed
Last update posted :
03/08/2022
Initiation :
03/10/2020
Primary completion :
10/10/2021
Completion :
02/10/2022
CD20 • CD19
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • YTS101
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (NCT04260932)
Phase 1
Hebei Yanda Ludaopei Hospital
Hebei Yanda Ludaopei Hospital
Completed
Phase 1
Hebei Yanda Ludaopei Hospital
Completed
Last update posted :
03/08/2022
Initiation :
03/01/2020
Primary completion :
05/10/2021
Completion :
09/10/2021
CD20 • CD19
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • YTS101
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (NCT04697290)
Phase 1
Beijing Tsinghua Chang Gung Hospital
Beijing Tsinghua Chang Gung Hospital
Suspended
Phase 1
Beijing Tsinghua Chang Gung Hospital
Suspended
Last update posted :
02/14/2022
Initiation :
03/10/2022
Primary completion :
03/10/2023
Completion :
06/10/2023
CD20 • CD19
|
CD20 positive • CD19 expression
|
cyclophosphamide • fludarabine IV • YTS101
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NCT05149391)
Phase 1
Peking University
Peking University
Recruiting
Phase 1
Peking University
Recruiting
Last update posted :
12/08/2021
Initiation :
07/20/2021
Primary completion :
07/01/2024
Completion :
10/01/2024
BCL2 • BCL6
|
CD20 positive
|
prizloncabtagene autoleucel (JNJ-4496)
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies (NCT04700319)
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co.,...
Recruiting
Phase 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recruiting
Last update posted :
03/08/2021
Initiation :
04/19/2019
Primary completion :
05/01/2021
Completion :
06/01/2021
CD20
|
CD20 positive
|
CD19/CD20 CAR T-cells
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (NCT04637503)
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Recruiting
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
11/19/2020
Initiation :
11/18/2020
Primary completion :
11/19/2020
Completion :
12/31/2023
CD276
|
4SCAR-T • GD2, PSMA and CD276 CAR-T
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03097770)
Phase 1/2
Chinese PLA General Hospital
Chinese PLA General Hospital
Completed
Phase 1/2
Chinese PLA General Hospital
Completed
Last update posted :
09/02/2020
Initiation :
04/01/2017
Primary completion :
05/10/2019
Completion :
01/31/2020
CD20
4SCAR-T Therapy Post CD19-targeted Immunotherapy (NCT04430530)
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Recruiting
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
05/31/2023
Completion :
12/31/2023
CD20 • CD38 • CD123 • CD22 • MME • IL3RA
|
4SCAR-T
Multi-CAR-T Cells Targeting B Cell Lymphomas (NCT04429438)
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Recruiting
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
07/31/2023
Completion :
12/31/2023
CD19 • CD79B • CD22 • CD70 • ANPEP
|
CD19 expression
|
multi-CAR-T cell therapy
Multi-4SCAR-T Therapy Targeting Breast Cancer (NCT04430595)
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Recruiting
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
05/31/2023
Completion :
12/31/2023
HER-2
|
HER-2 expression • CD44 expression
|
4SCAR-T
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma (NCT04169932)
Phase 1
Shanghai Longyao Biotechnology Inc., Ltd.
Shanghai Longyao Biotechnology Inc., Ltd.
Recruiting
Phase 1
Shanghai Longyao Biotechnology Inc., Ltd.
Recruiting
Last update posted :
11/20/2019
Initiation :
11/22/2019
Primary completion :
11/22/2022
Completion :
11/22/2022
CD20
|
CD20 expression
|
LY007
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies (NCT04156178)
Phase 1
iCell Gene Therapeutics
iCell Gene Therapeutics
Unknown status
Phase 1
iCell Gene Therapeutics
Unknown status
Last update posted :
11/12/2019
Initiation :
08/01/2018
Primary completion :
09/30/2020
Completion :
09/30/2020
CD20
|
CD20 expression • CD19 expression
|
CD20-CD19 cCAR T cells
CAR-T Immunotherapy Targeting CD19- ALL (NCT04016129)
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-Immune Medical Institute
Recruiting
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
09/19/2019
Initiation :
07/15/2019
Primary completion :
07/15/2021
Completion :
12/15/2023
CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA
|
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T
A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies (NCT02710149)
Phase 1/2
Southwest Hospital, China
Southwest Hospital, China
Unknown status
Phase 1/2
Southwest Hospital, China
Unknown status
Last update posted :
06/25/2019
Initiation :
03/01/2016
Primary completion :
03/01/2020
Completion :
03/01/2021
CD20
|
CD20 expression
CAR-T for R/R B-NHL (NCT03196830)
Phase 2
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Soocho...
Unknown status
Phase 2
The First Affiliated Hospital of Soochow Univer...
Unknown status
Last update posted :
04/16/2019
Initiation :
06/01/2017
Primary completion :
05/31/2021
Completion :
05/31/2021
CD20 • TNFRSF8 • CD22
|
CAR-T CD19/CD20/CD22/CD30
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login